Bank of America
CABA icon

Bank of America’s Cabaletta Bio CABA Stock Holding History

Bank of America’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$724K Buy
269,257
+254,865
+1,771% +$708K ﹤0.01% 4698
2025
Q4 		$31.5K Sell
14,392
-253,666
-95% -$629K ﹤0.01% 5957
2025
Q3 		$627K Sell
268,058
-230,185
-46% -$395K ﹤0.01% 5644
2025
Q2 		$757K Sell
498,243
-485,852
-49% -$758K ﹤0.01% 5470
2025
Q1 		$1.36M Buy
984,095
+437,634
+80% +$932K ﹤0.01% 5004
2024
Q4 		$1.24M Buy
546,461
+67,787
+14% +$238K ﹤0.01% 4841
2024
Q3 		$2.26M Buy
478,674
+309,569
+183% +$1.79M ﹤0.01% 4463
2024
Q2 		$1.26M Sell
169,105
-68,998
-29% -$846K ﹤0.01% 4751
2024
Q1 		$4.06M Buy
238,103
+77,583
+48% +$1.67M ﹤0.01% 3811
2023
Q4 		$3.64M Buy
160,520
+19,334
+14% +$325K ﹤0.01% 3814
2023
Q3 		$2.15M Buy
141,186
+115,688
+454% +$1.58M ﹤0.01% 4181
2023
Q2 		$329K Buy
25,498
+16,647
+188% +$181K ﹤0.01% 5528
2023
Q1 		$73.2K Buy
8,851
+7,626
+623% +$71.4K ﹤0.01% 6369
2022
Q4 		$11.3K Sell
1,225
-7,969
-87% -$29K ﹤0.01% 6887
2022
Q3 		$6K Sell
9,194
-6,053
-40% -$7.29K ﹤0.01% 7335
2022
Q2 		$16K Sell
15,247
-17,132
-53% -$24.2K ﹤0.01% 7239
2022
Q1 		$66K Buy
32,379
+25,268
+355% +$66.1K ﹤0.01% 7047
2021
Q4 		$27K Sell
7,111
-7,396
-51% -$78.9K ﹤0.01% 7429
2021
Q3 		$176K Sell
14,507
-5,698
-28% -$52.5K ﹤0.01% 6386
2021
Q2 		$174K Buy
20,205
+10,227
+102% +$100K ﹤0.01% 6186
2021
Q1 		$111K Buy
9,978
+6,808
+215% +$83.2K ﹤0.01% 6342
2020
Q4 		$40K Sell
3,170
-895
-22% -$11.6K ﹤0.01% 6400
2020
Q3 		$44K Sell
4,065
-2,594
-39% -$29.8K ﹤0.01% 6058
2020
Q2 		$75K Buy
6,659
+3,317
+99% +$25.4K ﹤0.01% 5803
2020
Q1 		$25K Buy
3,342
+2,207
+194% +$30.3K ﹤0.01% 6097
2019
Q4 		$16K Buy
+1,135
New +$13.4K ﹤0.01% 6543

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America's CABA Position: Q1 2026 in Review

Bank of America increased its Cabaletta Bio (CABA) stake by 1,771% in Q1 2026, buying an estimated $708K and bringing the position to 269,257 shares worth $724K. The position accounts for ﹤0.01% of the portfolio, ranked #4698.

Bank of America first reported a position in CABA in Q4 2019 and has held it in 26 quarters since. The position peaked at $4.06M in Q1 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • Bank of America held 269,257 shares of Cabaletta Bio worth $724K as of Q1 2026.
  • Bank of America bought 254,865 Cabaletta Bio shares in Q1 2026, an estimated $708K.
  • Cabaletta Bio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4698 holding.
  • Bank of America first reported a position in Cabaletta Bio in Q4 2019 and has held it in 26 quarters since.
  • Bank of America's Cabaletta Bio position peaked at $4.06M in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.